These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22283892)

  • 1. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K; Aspler A; Menzies D; Schwartzman K
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.
    Aspler A; Long R; Trajman A; Dion MJ; Khan K; Schwartzman K; Menzies D
    Thorax; 2010 Jul; 65(7):582-7. PubMed ID: 20627913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children.
    Cruz AT; Starke JR
    Int J Tuberc Lung Dis; 2014 Sep; 18(9):1057-61. PubMed ID: 25189552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
    Pina JM; Clotet L; Sala MR; Ferrer A; Arias C; Domínguez A
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):768-73. PubMed ID: 22508169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    PLoS One; 2011; 6(7):e22276. PubMed ID: 21789248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea.
    Park SH; Lee SJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Kim HJ; Menzies D
    Korean J Intern Med; 2016 May; 31(3):517-24. PubMed ID: 27052266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
    Menzies D; Dion MJ; Rabinovitch B; Mannix S; Brassard P; Schwartzman K
    Am J Respir Crit Care Med; 2004 Aug; 170(4):445-9. PubMed ID: 15172892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D
    Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
    Diel R; Loddenkemper R; Sotgiu G; Migliori GB
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1515. PubMed ID: 24200259
    [No Abstract]   [Full Text] [Related]  

  • 19. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
    Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D
    Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.